Zymeworks Inc (ZYME) |
|
38.18 0.4 (1.06%)
|
06-18 08:42 |
|
Open: |
37.54 |
Pre. Close: |
37.78 |
|
High:
|
38.61 |
Low:
|
37.35 |
|
Volume:
|
396,347 |
Market Cap:
|
1,763M |
|
|
|
|
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
38.924 - 39.079 |
39.079 - 39.212 |
|
Low:
|
37.029 - 37.217 |
37.217 - 37.379 |
|
Close:
|
37.854 - 38.162 |
38.162 - 38.427 |
|
Technical analysis |
as of: 2021-06-17 4:47:44 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 45.41 One year: 53.04 |
| Support: |
Support1: 31.25 Support2: 26.53 |
| Resistance: |
Resistance1: 38.88 Resistance2: 45.41 |
| Pivot: |
34.81 |
| Moving Average: |
MA(5): 37.97 MA(20): 33.36
MA(100): 33.60  MA(250): 38.33 |
| MACD: |
MACD(12,26): 2.24 Signal(9): 1.66 |
| Stochastic oscillator: |
%K(14,3): 93.61 %D(3): 95.86 |
| RSI: |
RSI(14): 73.48 |
| 52-week: |
High: 59.03 Low: 24.82 Change(%): 1.8 |
| Average Vol(K): |
3-Month: 42476 10-Days: 45048 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.ZYME has closed below upper band by 22.7%. Bollinger Bands are 26.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 17 Jun 2021
Zymeworks Inc (ZYME) gains 1.0590% for June 17 - Equities.com
Wed, 16 Jun 2021
Zymeworks Inc (ZYME) falls -1.1770% for June 16 - Equities.com
Tue, 15 Jun 2021
Zymeworks Inc (ZYME) gains 0.7380% for June 15 - Equities.com
Mon, 14 Jun 2021
Zymeworks Inc (ZYME) gains 0.5830% for June 14 - Equities.com
Wed, 09 Jun 2021
Zacks: Brokerages Expect Zymeworks Inc. (NYSE:ZYME) to Announce -$1.06 EPS - MarketBeat
Tue, 01 Jun 2021
Zymeworks Inc (ZYME) gains 2.6920% for June 01 - Equities.com
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
46 |
| Shares Float (M) |
40 |
|
% Held by Insiders
|
4.16 |
|
% Held by Institutions
|
75.24 |
|
Shares Short (K)
|
1,940 |
|
Shares Short P. Month (K)
|
2,000 |
Stock Financials |
|
EPS
|
-3.580 |
|
EPS Est This Year
|
-2.980 |
|
EPS Est Next Year
|
-2.540 |
|
Book Value (p.s.)
|
8.900 |
|
Profit Margin
|
|
|
Operating Margin
|
-481.19 |
|
Return on Assets (ttm)
|
-25.8 |
|
Return on Equity (ttm)
|
-55.1 |
|
Qtrly Rev. Growth
|
735.4 |
|
Gross Profit (p.s.)
|
-2.807 |
|
Sales Per Share
|
0.844 |
|
EBITDA (p.s.)
|
-3.988 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-151 |
|
Levered Free Cash Flow (M)
|
-98 |
Stock Valuations |
|
PE Ratio
|
-10.66 |
|
PEG Ratio
|
|
|
Price to Book value
|
4.29 |
|
Price to Sales
|
45.25 |
|
Price to Cash Flow
|
-11.64 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
